|
(Editing
August 2011...)
National
Coordinators
Team
Leader:
Shi-Ming
Chen ( 陈世明)
Professor
Founding
Director and CEO of Zhejiang Origin Bio-Tech Company Ltd
Hangzhou
Contact
address: chenshiming2008@yahoo.com.cn
Tel. 0086-10-63165181. No.1 Xian Nong Tan Str. Beijing, 100050, China.
Biography
Shi-Ming
Chen ( 陈世明)
is
the
Chinese NewPOL Team Leader (Principal NC).
He, an associate Professor, works in the Institute of Medical Materia,
Chinese Academy of Medical Sciences (中国医学科学院药物研究所)
http://www.imm.ac.cn.
He has engaged in the research and teaching work of Pharmacology and
Toxicology over twenty years. He worked in Germany BASF Company as a
Post-doctor for two years. He has published over 20 research papers and
books, and obtained 2 international patents and 2 National patents of
China, and made some achievements on Toxicology and Pharmacology in China.
Now he has been doing the research work of human neural stem cells.
***
Team Members (New)
1) Vacancy
2) Vacancy
3) Vacancy
4) ...
***
| |
CWIN (1, 2, ...) |
Pilot Schemes (1, 2, ...) |
WSWBQoLP |
IMIRC |
EU FP Calls for Proposals |
EU Non FP Calls for Proposals |
Non EU Calls for Proposals |
Private Project |
Other |
| Professor Shi-Ming Chen |
? |
? |
X |
X |
? |
|
|
X |
Stem Cells |
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
***
Team
Members (Temporary - Archive):
1) Li-Guo
Zhou ( 周立国)
is
a main member in China of the International Multidisciplinary Neuroscience
Research Center and International
Multidisciplinary Interface Research Congress.
He, a Professor, works in the Tong Ji Pharmic College, Hua Zhong
University of Science and Technology in China(华中科技大学同济药学院).
He has engaged in the research work and Teaching of Drug Toxicology about
30 years. He has published three books and 30 research papers, and has
obtained great achievements on Drug Toxicology in China.
Contact
address: zhoutjmu@hotmail.com
Tel. 0086-27-83657844. Hang Kong Road No.13, Wu Han City, 430030, China.
2)
Hai-Bo
Zhu ( 朱海波)
is a main member in China of the International
Multidisciplinary Neuroscience Research Center and International
Multidisciplinary Interface Research Congress.
He, an associate Professor, Ph.D, a group leader, works in the Institute
of Medical Materia, Chinese Academy of Medical Sciences(中国医学科学院药物研究所).
He has engaged in the research work and Teaching of Heart and Brain
Vascular Pharmacology over four years. He has published over 10 research
papers, and has obtained 5 national patents of China and great
achievements on Heart and Brain Vascular Pharmacology in China.
Contact
address: zhuhaibo@imm.ac.cn Tel.
0086-10-63188106. No.1 Xian Nong Tan Str. Beijing, 100050,China. http://www.imm.ac.cn/t_zhuhb.asp.
3)
Yu-Ming
Fan （范玉明）is
a main member in China of the International Multidisciplinary Neuroscience
Research Center and International
Multidisciplinary Interface Research Congress.
He, an associate Professor, a group leader,
works in the National Institute for the Control of Pharmaceutical
and Biological Products in China(中国药品生物制品检定所).
He has engaged in the research work on toxicology over ten years. He has
published over 20 research papers, and has obtained great achievements on
Toxicology of Pharmaceutical and Biological Products in China.
Contact
address: fanyuming60@hotmail.com
Tel. 0086-10-67872233-8220. No.2 Tian Tan Xi Li, Beijing, 100050, China.
Common
Areas of Interest:
1. Application studies of neural stem cell
transplantation for therapy of Alzheimer's disease (AD) and Parkinson’s
disease (PD) have been developed.
2. Human embryonic brain NSC cell
transplantation have been used for AD and PD and Stroke patients in
clinic.
3. New high throughout models of screening
new drugs of treating AD and PD have been establishing, such as promoting
NSC cell proliferation, anti-apoptosis and signal conduction and gene
transfer and other techniques. Screening new drugs of curing PA and AD
have been focused on Chinese traditional medicines and herbs and new
chemicals.
4. New drugs of treatment for cardiac and
brain vascular diseases have been selected and discovered.
5. New stem cells will be evaluated by
toxicology of biological products.
6. New drugs will be evaluated by drug
toxicology.
***
|
|
